+

WO2002000170A3 - Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer - Google Patents

Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer Download PDF

Info

Publication number
WO2002000170A3
WO2002000170A3 PCT/US2001/020444 US0120444W WO0200170A3 WO 2002000170 A3 WO2002000170 A3 WO 2002000170A3 US 0120444 W US0120444 W US 0120444W WO 0200170 A3 WO0200170 A3 WO 0200170A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
patients
radiosensitizers
targeted delivery
treatment
Prior art date
Application number
PCT/US2001/020444
Other languages
French (fr)
Other versions
WO2002000170A2 (en
Inventor
Ward Page Faulk
Original Assignee
Ward Page Faulk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ward Page Faulk filed Critical Ward Page Faulk
Priority to US10/311,302 priority Critical patent/US20040028686A1/en
Priority to EP01950547A priority patent/EP1305051A4/en
Priority to CA002414401A priority patent/CA2414401A1/en
Priority to AU2001271525A priority patent/AU2001271525A1/en
Priority to JP2002504953A priority patent/JP2004501171A/en
Priority to IL15358601A priority patent/IL153586A0/en
Publication of WO2002000170A2 publication Critical patent/WO2002000170A2/en
Publication of WO2002000170A3 publication Critical patent/WO2002000170A3/en
Priority to US11/952,181 priority patent/US20080095802A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to the targeted delivery of cytotoxic drugs: A) to lymphocytes responsible for the rejection of transplanted tissues, such as kidneys or hearts or bone marrow cells; B) the use of a non-toxic naturally existing delivery system to transport high concentrations of radiosensitizers to cancer cells; and C) to the targeted delivery of drugs in medical diagnosis and treatment of cancer.
PCT/US2001/020444 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer WO2002000170A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/311,302 US20040028686A1 (en) 2001-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplated organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
EP01950547A EP1305051A4 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
CA002414401A CA2414401A1 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
AU2001271525A AU2001271525A1 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
JP2002504953A JP2004501171A (en) 2000-06-28 2001-06-28 A) to activated lymphocytes in patients whose organs have been transplanted; B) as radiosensitizers to cancer cells in patients receiving radiation therapy; C) as drug carriers in cancer diagnosis and treatment. Targeted delivery of cytotoxins in vitamin binding proteins
IL15358601A IL153586A0 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
US11/952,181 US20080095802A1 (en) 2000-06-28 2007-12-07 Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21438900P 2000-06-28 2000-06-28
US21438800P 2000-06-28 2000-06-28
US21442700P 2000-06-28 2000-06-28
US60/214,389 2000-06-28
US60/214,427 2000-06-28
US60/214,388 2000-06-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/952,181 Continuation US20080095802A1 (en) 2000-06-28 2007-12-07 Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
WO2002000170A2 WO2002000170A2 (en) 2002-01-03
WO2002000170A3 true WO2002000170A3 (en) 2002-08-08

Family

ID=27395985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020444 WO2002000170A2 (en) 2000-06-28 2001-06-28 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer

Country Status (6)

Country Link
EP (1) EP1305051A4 (en)
JP (1) JP2004501171A (en)
AU (1) AU2001271525A1 (en)
CA (1) CA2414401A1 (en)
IL (1) IL153586A0 (en)
WO (1) WO2002000170A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092116A1 (en) 2001-05-15 2002-11-21 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
WO2002094271A1 (en) 2001-05-15 2002-11-28 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000935A (en) * 1985-08-02 1991-03-19 Faulk Ward P Treatment method utilizing transferrin-radioiodine conjugate
US5108987A (en) * 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US6150341A (en) * 1998-06-12 2000-11-21 Biotch Australia Pty Limited Vitamin B12 derivatives and methods for their preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US5792458A (en) * 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
CA2016584C (en) * 1989-05-17 1999-06-29 Robert S. Greenfield Anthracycline conjugates having a novel linker and methods for their production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108987A (en) * 1982-02-25 1992-04-28 Faulk Ward P Conjugates of proteins with anti-tumor agents
US5000935A (en) * 1985-08-02 1991-03-19 Faulk Ward P Treatment method utilizing transferrin-radioiodine conjugate
US6150341A (en) * 1998-06-12 2000-11-21 Biotch Australia Pty Limited Vitamin B12 derivatives and methods for their preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KISHIMOTO, T. ET AL.: "Receptors for transferrin and transcobalamin II display segregated distribution on microvilli of leukemia L1210 cells", BIOCHEM. BIPHYS. RES. COMMUN., vol. 146, no. 3, 14 August 1987 (1987-08-14), pages 1102 - 1108, XP002950815 *
WOODWARD ET AL.: "Enhanced allograft survival via simultaneous blockade of transferrin receptor and interleukin-2 receptor", TRANSPLANTATION, vol. 68, no. 9, 15 November 1999 (1999-11-15), pages 1369 - 1376, XP002950816 *

Also Published As

Publication number Publication date
WO2002000170A2 (en) 2002-01-03
CA2414401A1 (en) 2002-01-03
JP2004501171A (en) 2004-01-15
AU2001271525A1 (en) 2002-01-08
EP1305051A2 (en) 2003-05-02
IL153586A0 (en) 2003-07-06
EP1305051A4 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
Uchida et al. Slow release of anticancer drugs from porous calcium hydroxyapatite ceramic
EP2301531A3 (en) Combinations and modes of administration of therapeutic agents and combination therapy
EP2332542A3 (en) Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
AR042795A1 (en) BIOCOMPATIBLE DIALYSIS FLUIDS CONTAINING ICODEXTRINES
WO2003084470A3 (en) Compositions and methods for targeted biological delivery of molecular carriers
IL133253A0 (en) Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
GR3031509T3 (en) Keratinocyte growth factor (KGF) for its use in method of therapeutic treatment for the human or animal body.
US20220347212A1 (en) Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
IL153288A0 (en) Use of growth hormone or a derivative thereof in the preparation of a medicament for hematopoiesis
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
RU2335539C2 (en) Pharmaceutical preparation and method of malignant tumours treatment at the person using arginine deprivation
EP1226822A3 (en) Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same
WO2002000170A3 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
Hagenbeek et al. The effect of fractionated versus unfractionated total body irradiation on the growth of the BN acute myelocytic leukemia
MD2211G2 (en) Remedy for treatment of parodontium affections
WO2005028608A3 (en) Cell processor for use in the treatment of diseases
CN118812656B (en) A small molecule polypeptide TCMP-Y1 labeled with iodine-131 and its preparation method and application
Kolb et al. Dose rate and fractionation of total body irradiation in dogs: short and long term effects
WO2002045590A1 (en) Method for regional administeration of preparations for curing liver tumors
Kasakura Great contributions of E. Donnall Thomas to the development of clinical applications of bone marrow transplantation, leading to the 1990 Nobel Prize in Medicine/Physiology
BRPI0510062A (en) anthracycline derivatives
Zhou et al. Nanotechnology-driven strategies in postoperative cancer treatment: innovations in drug delivery systems

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 153586

Country of ref document: IL

Ref document number: 2414401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10311302

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001271525

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001950547

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001950547

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载